11/28
12:15 pm
rcus
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a "neutral" rating on the stock.
Low
Report
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a "neutral" rating on the stock.
11/18
04:05 pm
rcus
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Low
Report
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
11/1
11:00 am
rcus
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price [Yahoo! Finance]
Low
Report
Arcus Biosciences, Inc. (NYSE:RCUS) Just Reported Earnings, And Analysts Cut Their Target Price [Yahoo! Finance]
10/30
11:45 pm
rcus
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
10/30
11:35 pm
rcus
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Medium
Report
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
10/30
08:12 pm
rcus
Arcus Biosciences Announces Commencement of Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Arcus Biosciences Announces Commencement of Public Offering of Common Stock [Yahoo! Finance]
10/30
04:13 pm
rcus
Arcus Biosciences announces launch of public offering [Seeking Alpha]
Medium
Report
Arcus Biosciences announces launch of public offering [Seeking Alpha]
10/30
04:01 pm
rcus
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Low
Report
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
10/30
10:59 am
rcus
Arcus Biosciences (NYSE:RCUS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Arcus Biosciences (NYSE:RCUS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/30
10:39 am
rcus
Why Arcus Biosciences (RCUS) May Be Banking on Partnerships to Accelerate Its Immuno-Oncology Pipeline [Yahoo! Finance]
Low
Report
Why Arcus Biosciences (RCUS) May Be Banking on Partnerships to Accelerate Its Immuno-Oncology Pipeline [Yahoo! Finance]
10/29
08:10 pm
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $35.00 price target on by analysts at Wedbush. They now have an "outperform" rating on the stock.
Low
Report
Arcus Biosciences (NYSE:RCUS) was given a new $35.00 price target on by analysts at Wedbush. They now have an "outperform" rating on the stock.
10/29
04:01 pm
rcus
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Citigroup Inc. from $54.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Citigroup Inc. from $54.00 to $56.00. They now have a "buy" rating on the stock.
10/29
07:09 am
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $28.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Low
Report
Arcus Biosciences (NYSE:RCUS) was given a new $28.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
10/28
04:05 pm
rcus
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Low
Report
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
10/26
06:31 am
rcus
Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials [Yahoo! Finance]
Medium
Report
Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials [Yahoo! Finance]
10/20
09:53 am
rcus
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Wells Fargo & Company from $25.00 to $29.00. They now have an "overweight" rating on the stock.
Medium
Report
Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at Wells Fargo & Company from $25.00 to $29.00. They now have an "overweight" rating on the stock.
10/19
07:22 pm
rcus
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia [Yahoo! Finance]
Low
Report
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia [Yahoo! Finance]
10/19
07:00 pm
rcus
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Medium
Report
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
10/16
11:20 am
rcus
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets [Seeking Alpha]
Low
Report
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets [Seeking Alpha]
10/13
08:05 am
rcus
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/12
06:11 pm
rcus
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study [Yahoo! Finance]
High
Report
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study [Yahoo! Finance]
10/12
06:05 pm
rcus
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
High
Report
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
10/9
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Medium
Report
Arcus Biosciences Announces New Employment Inducement Grants
10/7
09:02 am
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $39.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was given a new $39.00 price target on by analysts at Truist Financial Corporation.
10/6
11:18 pm
rcus
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript [Seeking Alpha]
Medium
Report
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript [Seeking Alpha]